4 completed, 3 active not recruiting, 2 terminated, 1 recruiting. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Active not recruiting 3, Terminated 2, Recruiting 1, Suspended 1 |
| Phase 1 | 1 | Completed 1 |
Follow T-VEC: new trials by email Literature Review of T-VEC trials Research Report on T-VEC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease T-VEC - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Completed | The Netherlands Cancer Institute | 24 | 2020-09-08 | 2025-03-12 |
| Neoadjuvant T-VEC in High Risk Early Melanoma T-Vec - Melanoma | Phase 2 | Suspended | University of California, Davis | 6 | 2020-05-21 | 2023-09-15 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging - Leiomyosarcoma, Liposarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2019-12-31 | 2026-11-12 |
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma T-VEC - Angiosarcoma of Skin | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 5 | 2019-08-20 | 2022-11-01 |
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma Pembrolizumab, Talimogene Laherparepvec - Cutaneous Melanoma | Phase 2 | Recruiting | University of Louisville | 28 | 2019-07-03 | 2024-05-02 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Pembrolizumab, Talimogene Laherparepvec - Advanced Melanoma, Recurrent Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 43 | 2018-06-05 | 2026-05-20 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-11-12 |
| Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Talimogene Laherparepvec - Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2016-08-01 | 2023-01-25 |
| Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Talimogene laherparepvec, Ipilimumab - Melanoma | Phase 1 / Phase 2 | Completed | Amgen | 217 | 2013-02-07 | 2024-05-14 |
| An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) Talimogene Laherparepvec - Melanoma | Phase 2 | Completed | BioVex Limited | 3 | 2008-08-01 | 2015-12-17 |
| A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Talimogene Laherparepvec - Melanoma | Phase 2 | Completed | BioVex Limited | 50 | 2005-12-01 | 2015-12-18 |
Melanoma (7) · Adenocarcinoma, Papillary (1) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Signet Ring Cell (1) · Eccrine Porocarcinoma (1) · Hemangiosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Inflammatory Breast Neoplasms (1) · Leiomyosarcoma (1) · Liposarcoma (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1)
National Cancer Institute (NCI) (3) · BioVex Limited (2) · Amgen (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · The Netherlands Cancer Institute (1) · University of California, Davis (1) · University of Louisville (1)
United States (9) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · United Kingdom (1)
Cameron Gaskill, MD (1) · John Haanen, Prof. (1) · John Mullinax, MD, (1) · John Nemunaitis, MD (1) · Michael C Lowe, MD (1) · Michael Egger, MD (1) · Naoto T Ueno (1) · Rob Coffin, PhD (1) · Siwen Hu-Lieskovan (1) · Steven I Robinson (1)
PMID 35115306, PMID 35927710, PMID 38664936
UM1CA186709 (2), P30CA016672 (1), U10CA180888 (1), UM1CA186686 (1), UM1CA186716 (1)